Skip to main content
logo
Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
4.280
-0.150 (-3.39%)
At close: Jul 20, 2026, 4:00 PM EDT
4.450
+0.170 (3.97%)
After-hours: Jul 20, 2026, 7:38 PM EDT

Radiopharm Theranostics Income Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22
Revenue
3.643.630.30.29-
Revenue Growth (YoY)
116.02%1114.26%2.35%--
Cost of Revenue
3.263.59---
Gross Profit
0.370.040.30.29-
Selling, General & Admin
16.6614.6413.0412.237.64
Research & Development
35.2427.5223.0922.637.49
Other Operating Expenses
-5.44-3.9411.38-0.085.9
Total Operating Expenses
46.4638.2147.5134.7821.03
Operating Income
-46.68-38.17-47.21-34.49-21.03
Interest Expense
-0.13-0.07-0.64-0.09-9.35
Total Non-Operating Income (Expense)
-0.13-0.07-0.64-0.09-9.35
Pretax Income
-46.81-38.24-47.85-34.57-30.38
Provision for Income Taxes
0.140.10.10.040.04
Net Income
-46.94-38.34-47.95-34.61-30.42
Minority Interest in Earnings
-1.28----
Net Income to Common
-26.97-38.34-47.95-34.61-30.42
Shares Outstanding (Basic)
107111
Shares Outstanding (Diluted)
107111
Shares Change (YoY)
157.88%438.49%26.36%68.74%-
EPS (Basic)
-5.37-5.28-37.23-33.96-50.34
EPS (Diluted)
-5.37-5.28-37.23-33.96-50.34
Free Cash Flow
-7.03-36.65-22.98-23.25-9.91
Free Cash Flow Per Share
-0.72-5.28-17.84-22.80-16.40
Gross Margin
10.27%1.08%100.00%100.00%-
Operating Margin
-1283.96%-1050.63%-15777.20%-11796.10%-
Profit Margin
-1291.31%-1055.27%-16024.30%-11838.60%-
FCF Margin
-193.30%-1008.57%-7678.40%-7951.56%-
EBITDA
-46.68-35.58-44.08-31.19-18.04
EBITDA Margin
-1283.96%-979.19%-14732.40%-10668.60%-
EBIT
-46.68-38.17-47.21-34.49-21.03
EBIT Margin
-1283.96%-1050.63%-15777.20%-11796.10%-
Effective Tax Rate
-0.29%-0.27%-0.20%-0.11%-0.15%
SEC Filings: 10-K · 10-Q